NasdaqGS:ALNYBiotechs
Alnylam Pharmaceuticals (ALNY) On Lowered TTR Guidance And What It Means For Valuation
Alnylam Pharmaceuticals (ALNY) is back in focus after its 28.35% intraday share price drop on July 30, 2026, following lowered 2026 TTR product sales guidance despite solid reported quarterly revenue and net income.
See our latest analysis for Alnylam Pharmaceuticals.
Set against this earnings release and guidance change, Alnylam Pharmaceuticals' share price has been under pressure for much of 2026, with a year to date share price return down 42.84% and a 1 year total shareholder return down...